Lunai Bioworks Inc.
LNAINasdaq
$2.82
↓ -2.1%Jul 17 close · end-of-day
Price
1Y↑ +4.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$70.5M
Enterprise Value
$67.3M
P/E
1.4
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$128.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
1342.8%
ROIC
—
Debt / Equity
—
Net Cash
$3.2M
Return 1Y
+11.9%
Company profile
Enochian Biosciences, Inc. engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment.
- CEO
- Mark R. Dybul
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- enochianbio.com
Earnings
LNAI Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20,942.00—
Diluted EPS-$0.10—
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.4M | -$116.1M | -$38.6M | -$81.6M | -$189.0M |
| Net income | -$26.7M | -$113.4M | -$39.7M | -$88.4M | -$178.0M |
| Diluted EPS | — | -$2.16 | -$0.71 | -$0.91 | -$1.08 |
| Operating cash flow | -$20.6M | -$15.7M | -$11.8M | -$11.0M | -$7.9M |
| Free cash flow | -$20.7M | -$15.7M | -$11.8M | -$11.0M | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $20,942.00 |
| Gross profit | — | — | — | — | — | — | — | $20,942.00 |
| Operating income | -$17.1M | -$53.3M | -$4.5M | -$4.2M | -$126.9M | -$3.3M | -$1.8M | -$1.5M |
| Net income | -$15.7M | -$44.2M | -$7.3M | $189,176.00 | -$126.7M | $2.8M | -$1.8M | -$2.6M |
| Diluted EPS | -$0.16 | -$2.76 | -$0.45 | $0.00 | $2.13 | $0.13 | -$0.08 | -$0.10 |
| Operating cash flow | -$2.4M | -$2.0M | -$2.6M | -$1.5M | -$1.8M | -$1.3M | -$1.1M | -$1.0M |
| Free cash flow | — | — | — | — | — | — | — | -$1.0M |
| Gross margin | — | — | — | — | — | — | — | 100.0% |
| Operating margin | — | — | — | — | — | — | — | -7054.1% |
| Net margin | — | — | — | — | — | — | — | -12278.6% |
Company news
Jun 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.